XTL Biopharmaceuticals Ltd ADR (XTLB NASDAQ) stock market data APIs
$0.9917
-0.05(-5%)
as of January 16, 2026
Try our APIs with
free plan!
XTL Biopharmaceuticals Ltd ADR Financial Data Overview
Price chart is built with
Anychart
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Prev. Close
0.9917
Open
0.946
High
1.0229
Low
0.8577
52 wk Range
0.53-2.5699
Market Cap
9 342 K
Shares Outstanding
9 462 K
Revenue
968 K
EPS
0
Beta
0.78
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get XTL Biopharmaceuticals Ltd ADR data using free add-ons & libraries
Get XTL Biopharmaceuticals Ltd ADR Fundamental Data
XTL Biopharmaceuticals Ltd ADR Fundamental data includes:
- Net Revenue: 968 K
- EBITDA: -1 973 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
XTL Biopharmaceuticals Ltd ADR News
New
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved diseas...
XTL Biopharmaceuticals receives Nasdaq bid price deficiency notice
* XTL Biopharmaceuticals (XTLB [https://seekingalpha.com/symbol/XTLB]) received [https://seekingalpha.com/pr/20349010-xtl-announces-receipt-of-nasdaq-notification-letter-regarding-minimum-bid-price-...
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification l...
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
XTL Biopharmaceuticals Ltd. RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
